Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05895825
PHASE1
A Study of EOC237 in Patients With Advanced Solid Tumor
Sponsor: Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
View on ClinicalTrials.gov
Summary
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
Official title: A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2023-07-26
Completion Date
2026-09-30
Last Updated
2023-11-02
Healthy Volunteers
No
Conditions
Interventions
DRUG
EOC237
EOC237 for orally
Locations (1)
National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China